These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

337 related items for PubMed ID: 18928173

  • 1. [Chronic inflammation, oxidative stress and effects of erythropoetin in end-stage renal disease patients].
    Lazarević T, Stojimirović B, Poskurica M, Lazarević M, Mitrović N, Stolić R.
    Med Pregl; 2007; 60 Suppl 2():109-13. PubMed ID: 18928173
    [Abstract] [Full Text] [Related]

  • 2. Erythropoietin requirements: a comparative multicenter study between peritoneal dialysis and hemodialysis.
    Coronel F, Herrero JA, Montenegro J, Fernandez C, Gandara A, Conesa J, Rivera MT, Torrente J, Portolés J, Gomez-Martino JR.
    J Nephrol; 2003; 16(5):697-702. PubMed ID: 14733416
    [Abstract] [Full Text] [Related]

  • 3. Long-term erythropoietin therapy does not affect metalloproteinases and their inhibitor levels, oxidative stress and inflammation in hemodialyzed patients.
    Pawlak K, Pawlak D, Mysliwiec M.
    Am J Nephrol; 2007; 27(3):221-5. PubMed ID: 17384500
    [Abstract] [Full Text] [Related]

  • 4. Nutritional-inflammation status and resistance to erythropoietin therapy in haemodialysis patients.
    Locatelli F, Andrulli S, Memoli B, Maffei C, Del Vecchio L, Aterini S, De Simone W, Mandalari A, Brunori G, Amato M, Cianciaruso B, Zoccali C.
    Nephrol Dial Transplant; 2006 Apr; 21(4):991-8. PubMed ID: 16384825
    [Abstract] [Full Text] [Related]

  • 5. The effect of high-flux hemodialysis on renal anemia.
    Ayli D, Ayli M, Azak A, Yüksel C, Kosmaz GP, Atilgan G, Dede F, Abayli E, Camlibel M.
    J Nephrol; 2004 Apr; 17(5):701-6. PubMed ID: 15593038
    [Abstract] [Full Text] [Related]

  • 6. Red blood cell membrane lipid peroxidation and resistance to erythropoietin therapy in hemodialysis patients.
    Gallucci MT, Lubrano R, Meloni C, Morosetti M, Manca di Villahermosa S, Scoppi P, Palombo G, Castello MA, Casciani CU.
    Clin Nephrol; 1999 Oct; 52(4):239-45. PubMed ID: 10543326
    [Abstract] [Full Text] [Related]

  • 7. Lymphocyte 5'-nucleotidase and aminopeptidase N activity in patients on maintenance hemodialysis treated with human recombinant erythropoietin and 1-alpha-D3.
    Stefanovic V, Mitić-Zlatkovic M, Radivojevic J, Vlahovic P.
    Ren Fail; 2005 Oct; 27(3):283-8. PubMed ID: 15957544
    [Abstract] [Full Text] [Related]

  • 8. Effect of intravenous ascorbic acid in hemodialysis patients with EPO-hyporesponsive anemia and hyperferritinemia.
    Attallah N, Osman-Malik Y, Frinak S, Besarab A.
    Am J Kidney Dis; 2006 Apr; 47(4):644-54. PubMed ID: 16564942
    [Abstract] [Full Text] [Related]

  • 9. [Optimal therapy with erythropoietin (EPO) in patients with renal anemia on hemodialysis therapy].
    Merta M, Sobotová D, Zahálková J, Bitterová Z, Jirka T, Knetl P, Kopenec J, Suchanová J, Vlasák J.
    Sb Lek; 2001 Apr; 102(1):41-52. PubMed ID: 11830918
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Chronic inflammation and mortality in haemodialysis: effect of different renal replacement therapies. Results from the RISCAVID study.
    Panichi V, Rizza GM, Paoletti S, Bigazzi R, Aloisi M, Barsotti G, Rindi P, Donati G, Antonelli A, Panicucci E, Tripepi G, Tetta C, Palla R, RISCAVID Study Group.
    Nephrol Dial Transplant; 2008 Jul; 23(7):2337-43. PubMed ID: 18305316
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Outcome data on pediatric dialysis patients from the end-stage renal disease clinical indicators project.
    Brem AS, Lambert C, Hill C, Kitsen J, Shemin DG.
    Am J Kidney Dis; 2000 Aug; 36(2):310-7. PubMed ID: 10922309
    [Abstract] [Full Text] [Related]

  • 19. Decreased erythropoietin requirements in maintenance hemodialysis patients with statin therapy.
    Sirken G, Kung SC, Raja R.
    ASAIO J; 2003 Aug; 49(4):422-5. PubMed ID: 12918584
    [Abstract] [Full Text] [Related]

  • 20. Impact of elevated C-reactive protein levels on erythropoiesis- stimulating agent (ESA) dose and responsiveness in hemodialysis patients.
    Bradbury BD, Critchlow CW, Weir MR, Stewart R, Krishnan M, Hakim RH.
    Nephrol Dial Transplant; 2009 Mar; 24(3):919-25. PubMed ID: 18840893
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.